REG3A and graft versus host disease: REG3α concentrations were 3-fold higher at the time of GVHD diagnosis in patients who had no response to therapy at 4 weeks than in patients who experienced a complete or partial response; patients responding to therapy still exhibited REG3α concentrations more than 3 times that of non-GVHD controls.